AstraZeneca plc (LON: AZN) fell 1.3 percent and GSK plc (LON: GSK) dropped 1.5 percent on Tuesday April 21, making the pharmaceutical sector the weakest performer in the FTSE 100 as investors rotated away from large-cap drug names and into utilities and defensive consumer stocks in a session shaped more by macro positioning than company-specific news.
The moves were not driven by any individual earnings release or pipeline event from either company, but reflected the broader defensive reallocation playing out as the Iran ceasefire deadline approached.
AstraZeneca, which has been one of the FTSE 100’s most consistent performers over the past three years driven by its oncology and rare disease pipeline, entered the session close to the £130 area. The stock has benefited throughout the Iran war period from its low direct exposure to energy cost volatility and its predominantly dollar-denominated revenue base, which provides a natural hedge against sterling movements.
However, with utilities offering a more direct play on the energy infrastructure theme in a prolonged oil supply disruption environment, some rotation out of pharma and into regulated utility names was visible across the UK session.
GSK, which reports Q1 2026 results in early May, traded around the £18 area following the April 21 session decline. The stock has been managing investor expectations around its specialty medicines pipeline following several years in which its respiratory and HIV franchises have delivered solid but unspectacular growth against a backdrop of elevated R&D spending.
Wells Fargo has flagged GSK’s vaccine division as a potential re-rating catalyst in the second half of 2026 if respiratory syncytial virus vaccine uptake data through the northern hemisphere season comes in above expectations. Neither AstraZeneca nor GSK provided specific commentary on April 21 related to the session’s price moves.
The broader FTSE 100 pharmaceutical and healthcare weighting has historically provided the index with resilience during periods of global uncertainty, but on April 21 the defensive rotation favoured energy infrastructure over drug stocks, a rotation that reflects the specific character of the current risk environment — an oil supply shock rather than a broad growth slowdown — which makes utilities a more natural port in the storm than pharmaceuticals for the current macro moment. The FTSE 100 closed the session at approximately 10,498, down from the morning’s high of around 10,634.